J Korean Ophthalmol Soc.  2015 Jun;56(6):811-814. 10.3341/jkos.2015.56.6.811.

Comparative Study of Hugel-tox(R) versus Botox(R) for the Treatment of Essential Blepharospasm

• Lee JH
• Jung SK
• Baik JS
• Yang SW

• KMID: 2339143
• DOI: http://doi.org/10.3341/jkos.2015.56.6.811

Abstract

PURPOSE
To compare clinical efficacy and duration of Hugel-tox(R) (also known as Botulax(R)) and Botox(R) for the treatment of essential blepharospasm.
METHODS
A total of 48 patients who were injected with Hugel-tox(R) (17 females, 7 males) or Botox(R) (18 females, 6 males) from February 2013 to October 2013 were enrolled in the present study. Changes in eyelid closing force and Scott grade before and after injection were analyzed. Adverse events were also evaluated.
RESULTS
There were no significant differences between the Hugel-tox(R) and Botox(R) groups in clinical efficacy and duration. Before and after injection, changes in Scott grade (Hugel-tox(R): -1.17 +/- 0.70, Botox(R): -1.21 +/- 0.72, p = 0.840), changes in eyelid closing force (Hugel-tox(R): -1.38 +/- 0.58, Botox(R): -1.17 +/- 0.56, p = 0.212) and duration (Hugel-tox(R): 116.08 +/- 22.12 days, Botox(R): 126.92 +/- 38.94 days, p = 0.242) were shown. No serious adverse events were found in either group.
CONCLUSIONS
Hugel-tox(R) showed nearly equal efficacy and duration compared with Botox(R).

Keyword

Botox; Essential blepharospasm; Hugel-tox

MeSH Terms

Blepharospasm*
Eyelids
Female
Humans

Reference

References

1. Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008; 115:585–91.

2. Naumann M, Albanese A, Heinen F, et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006; 13(Suppl 4):35–40.

3. Biuk D, Karin AA, Matić S, et al. Quality of life in patients with blepharospasm. Coll Antropol. 2013; 37:29–33.

4. Streitová H, Bareš M. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta Neurol Belg. 2014; 114:285–91.

5. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985; 103:347–50.

6. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007; 52:13–31.

7. Sampaio C, Ferreira JJ, Simões F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1. Mov Disord. 1997; 12:1013–8.

8. Rieder CR, Schestatsky P, Socal MP, et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007; 30:39–42.

9. Pagan FL, Harrison A. A guide to dosing in the treatment of cer-vical dystonia and blepharospasm with Xeomin(R): a new botulinum neurotoxin A. Parkinsonism Relat Disord. 2012; 18:441–5.

10. Shin JH, Jeon C, Woo KI, Kim YD. Clinical comparability of Dysport and Botox in essential blepharospasm. J Korean Ophthalmol Soc. 2009; 50:331–5.

11. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin(R) versus Botox(R) in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009; 23:137–41.